[The 131I-fibrinogen turnover during activation of blood fibrinolysis].
The influence of stanozolol Stromba and phenformin Dibotin (Winthrop) and complamin (Wulfing) on transformation of 131J-fibrinogen administered intravenously was examined in 39 patients with arteriosclerosis obliterans. The patients were divided into 3 groups; one of the groups included untreated patients. Radioactivity of the plasma and of the urine was determined by means of a scintillation counter. The volume of plasma, plasma fibrinogen (g%, g, g/kg), half time of persistance (T 1/2) and degradation of fibrinogen were determined. The patients who received Dibotin and Stromba simultaneously showed statistically significant decrease of the plasma fibrinogen degradation im comparison to the control group. But in patients who received complamin in spite of significant decrease of the plasma fibrinogen (g%), the fibrinogen degradation was not different from the value obtained in the group.
D000328:Adult; D001161:Arteriosclerosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007455:Iodine / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use*; D013197:Stanozolol / Q000627:therapeutic use*; D014971:Xanthinol Niacinate / Q000627:therapeutic use
D013197:Stanozolol; D014971:Xanthinol Niacinate; D007455:Iodine; D010629:Phenformin
Untersuchungen über den 131J-Fibrinogenumsatz bei der Aktivierung der Blutfibrinolyse